BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells
- PMID: 12700661
- DOI: 10.1038/sj.onc.1206425
BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells
Abstract
The p85alpha subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85alpha null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85alpha null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCgamma (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85alpha, Btk, BLNK and PLCgamma) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (G0) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca(2+) entry (SK&F 96365) or PKC (Gö6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca(2+) and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.
Similar articles
-
BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.Oncogene. 2001 Nov 1;20(50):7352-67. doi: 10.1038/sj.onc.1204951. Oncogene. 2001. PMID: 11704865
-
Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.J Immunol. 1999 Apr 15;162(8):4438-46. J Immunol. 1999. PMID: 10201980
-
Phosphatidylinositol 3-kinase is required for the transcriptional activation of cyclin D2 in BCR activated primary mouse B lymphocytes.Eur J Immunol. 2005 Sep;35(9):2748-61. doi: 10.1002/eji.200425812. Eur J Immunol. 2005. PMID: 16114097
-
Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.Immunol Res. 2001;23(2-3):147-56. doi: 10.1385/IR:23:2-3:147. Immunol Res. 2001. PMID: 11444380 Review.
-
Role of Btk in B cell development and signaling.Curr Opin Immunol. 1997 Aug;9(4):534-40. doi: 10.1016/s0952-7915(97)80107-0. Curr Opin Immunol. 1997. PMID: 9287186 Review.
Cited by
-
PIK3IP1 Promotes Extrafollicular Class Switching in T-Dependent Immune Responses.J Immunol. 2020 Oct 15;205(8):2100-2108. doi: 10.4049/jimmunol.2000584. Epub 2020 Sep 4. J Immunol. 2020. PMID: 32887751 Free PMC article.
-
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.Mol Cell Biol. 2004 Nov;24(22):10058-71. doi: 10.1128/MCB.24.22.10058-10071.2004. Mol Cell Biol. 2004. PMID: 15509806 Free PMC article.
-
A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells.J Biol Chem. 2011 Sep 16;286(37):32054-63. doi: 10.1074/jbc.M111.271247. Epub 2011 Jul 22. J Biol Chem. 2011. PMID: 21784852 Free PMC article.
-
Cardiotoxicity of Novel Targeted Hematological Therapies.Life (Basel). 2020 Dec 11;10(12):344. doi: 10.3390/life10120344. Life (Basel). 2020. PMID: 33322351 Free PMC article. Review.
-
Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.Medchemcomm. 2018 Mar 13;9(4):697-704. doi: 10.1039/c8md00019k. eCollection 2018 Apr 1. Medchemcomm. 2018. PMID: 30108960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous